



BPS Oncology Exam

Total Question: 175

BPS-Oncology Part 1

Question: 1

A 3-year-old girl diagnosed with ALL developed an urticarial rash on her upper body extremities and experienced mild bronchospasm 30 minutes into the infusion of her day-15 pegaspargase. The infusion was discontinued, and supportive care measures were instituted. Today is day 43, and the patient is due for her next scheduled dose of pegaspargase.

Which is the most appropriate course of action in this situation?

- A. Substitute six doses of asparaginase *Erwinia chrysanthemi* for the one dose of pegaspargase.
- B. Substitute nine doses of asparaginase *Erwinia chrysanthemi* for the one dose of pegaspargase.
- C. Resume therapy with pegaspargase, but premedicate the dose with acetaminophen, diphenhydramine, and a corticosteroid.
- D. Discontinue all further treatment with any form of asparaginase therapy.

Answers: A

Question: 2

Which organization would provide the best initial consumer information about taking tamoxifen to prevent breast cancer?

- A. American College of Obstetricians and Gynecologists
- B. American Society of Clinical Oncology
- C. American Cancer Society
- D. American College of Surgeons

Answers: A

Question: 3

In which of the following settings would hemorrhagic cystitis associated with cyclophosphamide administration be most likely to occur?

- A. Adjuvant therapy for breast cancer
- B. Induction therapy for ALL
- C. Initial therapy for aggressive non-Hodgkin lymphoma
- D. Preparative regimen for hematopoietic cell transplantation

Answers: D

Question: 4

Which of the following statements is true regarding ado-trastuzumab emtansine?

- A. Binds to domain II of the HER-2 receptor extracellular domain, preventing the natural ligand from binding and activation cell signaling and subsequent growth
- B. Binds to domain IV of the HER-2 receptor extracellular domain, preventing the natural ligand from binding and activating cell signaling and subsequent growth
- C. Binds to domain IV of the HER-2 receptor extracellular domain, leading to receptor-antibody complex internalization and release of the cytotoxic moiety
- D. Prevents dimerization of HER-2 and HER-3 receptors, inhibiting downstream signaling through the MAP-K/AKT pathway

Answers: C

Question: 5

A 17-year-old patient is enrolled in a clinical protocol for the treatment of newly diagnosed osteosarcoma. The initial consent is signed by the patient's legal guardians, and the patient assented for enrollment in the study. The patient is now 18 years old, is considered an adult in his state, and is due for the next cycle of chemotherapy per the protocol.

What must the Oncology pharmacist confirm before dispensing chemotherapy for this patient?

- A. That the patient has consented to the protocol
- B. That the patient has consented to the protocol and that the legal guardian has assented
- C. That a copy of the patient's original consent document is available
- D. The patient's assent to continue treatment on protocol

Answers: C

Question: 6

A patient who is receiving tamoxifen for recurrent breast cancer complains of significant hot flashes. Which of the following has/have demonstrated benefit in clinical trials for the treatment of vasomotor symptoms?

- A. L-carnitine
- B. Foot reflexology